You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Inducible HMGB1 antagonist for viral-induced acute lung injury.

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NHLBI

    For more than a decade, our work has focused on development of therapeutic interventions for viral- and bacterial-induced acute lung injury (ALI) and the more severe acute respiratory distress syndrome (ARDS). Significantly, we identified the Toll-like receptor 4 (TLR4) signaling pathway as key to the host response to influenza and secondary bacterial infection following influenza. We also identif ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a portable beat-to-beat fetal ECG system

    SBC: AUSCULTECH DX LLC            Topic: NICHD

    Project Summary There are 24,000 stillbirths per year in the United States, and 2.6 million stillbirths per year worldwide, with no significant decrease in the last decade. Abnormal fetal heart rhythms, such as long QT syndrome, are thought to play an important role in these deaths, and may cause 3- 10% of unexplained stillbirths. This is in addition to known fetal arrhythmias, which affect 1-3% o ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. An immunotherapeutic IgY formulation against norovirus diarrhea

    SBC: SCALED MICROBIOMICS LLC            Topic: NIAID

    Project Summary/Abstract for STTR Phase I Application: An immunotherapeutic IgY formulation against norovirus diarrhea Human norovirus (HuNoV) infects millions of people globally each year, causing diarrheal illness resulting in more than 200,000 deaths annually, particularly in the very young, the very old, and the immunocompromised. There is currently neither an effective vaccine nor effective t ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Precision Glycoengineering of an HCV Envelope-Based Nanoparticle Vaccine

    SBC: NeuImmune, Inc.            Topic: NIAID

    ABSTRACTGlobally, more than 71 million people are infected with Hepatitis C virus (HCV), with 1-2 million new infections occurring each year. This major health concern necessitates the development of an effective vaccine. Since HCV rapidly accumulates mutations, vaccines must elicit the production of broadly neutralizing antibodies (bnAbs) in a reproducible fashion. The viral envelope E1E2 glycopr ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. 3D microprinting-enabled microinjection needle arrays for enhanced therapeutics delivery into the brain

    SBC: SEETRUE TECHNOLOGY, LLC            Topic: 101

    PROJECT SUMMARY Microinjection technologies underlie many research and clinical applications that require gene and cell delivery, including studies and emerging treatments of neurological conditions (e.g., neurodegenerative diseases, traumatic brain injury, and cancer). Unfortunately, challenges associated with the microinjection tools by which the viral vectors and cells inherent in these applica ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

    SBC: NANOVALENT PHARMACEUTICALS INC            Topic: 102

    Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Using Interactive Digital Media to Teach Cardiopulmonary Resuscitation to High School Students

    SBC: CORAM TECHNOLOGIES, INC.            Topic: 500

    Abstract Out-of-hospital cardiac arrest affects over 350,000 people in the U.S. annually, but only 10.8% survive. Bystander cardiopulmonary resuscitation (CPR) improves survival, but rates of training in the U.S. are low. It is recently required by law in 39 U.S. states that high school students learn CPR. However, current methods of teaching CPR use outdated pedagogical strategies and expensive d ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Design and Engineering of Biodegradable 3D Nanoprinted Microcarriers for HIV Drug Delivery

    SBC: INFRATRAC INC            Topic: NIAID

    Precise, customizable drug delivery remains a long-term goal, for HIV in particular, as such technologies would allow therapies tailored to a patient’s biological makeup and potentially improve adherence. Extended-release methods address part of the issue, but face limitations. A novel drug delivery system could offer better pediatric dosing, via both oral and new routes of administration. Exist ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate

    SBC: Tengen Biomedical Co            Topic: NIAID

    Developing Vertebrate-Specific Replication-Defective Dengue Virus asa Novel Single-Cycle Dengue Vaccine Candidate Abstract With an estimated minimum of 390 million dengue virus (DENV) infections per year, the DENV epidemic was listed as one of the world's top 10 public health threats by WHO in 2019. At present, there is no specific treatment. A universal vaccine is urgently needed. DENV vaccine de ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government